Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17573369 | 0.82 | LRRK2 (1.00) | LRRK2EGLN2EGLN1EGLN3 | |
| SCHEMBL17573286 | 0.81 | LRRK2 (0.70) | LRRK2 | |
| SCHEMBL17573300 | 0.80 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL17573378 | 0.79 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL17573292 | 0.79 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL17573293 | 0.78 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL18399207 | 0.78 | LRRK2 (0.86) | LRRK2 | |
| SCHEMBL18399160 | 0.78 | LRRK2 (0.86) | LRRK2 | |
| SCHEMBL17573365 | 0.77 | LRRK2 (0.58) | LRRK2 | |
| SCHEMBL18399251 | 0.76 | LRRK2 (0.58) | LRRK2HTTSMN1; SMN2EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190889-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10954240-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2016036586-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954240-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | LRRK2, LRRC59, LRRC47 | LRRK2 1/4885HTT 407/4885SMN1; SMN2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.